The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
about
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer TherapyPrecision medicine for cancer with next-generation functional diagnosticsExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationInhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXASurvivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1.Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancersThe Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL AntagonismTargeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.Comparative transcriptomics of elasmobranchs and teleosts highlight important processes in adaptive immunity and regional endothermy.A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in CholangiocarcinomaTumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress.Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.Interactome of E. piscicida and grouper liver proteins reveals strategies of bacterial infection and host immune response.FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor.(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice.KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer.Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.Pleurotus nebrodensis polysaccharide(PN50G) evokes A549 cell apoptosis by the ROS/AMPK/PI3K/AKT/mTOR pathway to suppress tumor growth.miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.The influential role of BCL2 family members in synovial sarcomagenesis.Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.The Critical Role of Rab31 in Cell Proliferation and Apoptosis in Cancer Progression.Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.BCL-W has a fundamental role in B cell survival and lymphomagenesis.PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiationTargeting apoptosis in acute myeloid leukaemia.
P2860
Q26740207-89FC6F36-EC6C-4766-9CA8-23A03043841EQ26780232-D2835B19-6653-4E17-A7B7-E3CC761FA636Q28118450-E45E2B2C-F4FF-4A64-8AD9-54A4642446B0Q28830560-968A1FD5-1A48-47EC-B545-B31EEE8D790AQ33634679-776F8EA0-C8B6-45CA-A682-6FF3A38E69CBQ33674312-69A5777E-4F70-4C09-B92F-D59215F9355BQ33701925-BF643A1C-154D-45F7-B236-E7F0E6F67B7EQ35925179-A025C30B-C65B-4A4D-8EE6-6656D391A401Q36092931-994CF62A-F6AE-4D37-B431-FC6079EC43E8Q36192485-009FFF38-60B9-453C-A421-50F3EA273FEBQ36263368-996190D6-BB98-4DCD-BA4A-240637BB81B3Q36778814-A319DC63-EB86-442F-A276-60199E711C15Q36989342-87BFB8BC-DA98-4023-A934-552A4861B9AEQ37271200-6200B317-4DFC-402A-B30C-1497B04E67A9Q37416797-5CCD1FDB-AB21-47BD-9B73-64C8305E25AAQ37550238-1366533D-D6B2-439A-A7D5-3B72EA376411Q37580764-48897E7D-1C78-441A-8E60-60478FAE559BQ37690890-FA9C3530-2465-49AC-A85C-0FA12ED3A299Q38563530-F603BEA4-14AB-4450-B65F-5029B9FEB570Q38633144-DD03DADB-664F-4C9D-BD96-F1E157195AE6Q38722012-8F2A72B0-920B-4EF5-B6BB-236FEDF49BE3Q38722346-442BC342-7637-4BC0-B122-3B8770DF7602Q38743654-03BEF859-D369-4DC8-9DA4-E33819100E0BQ38743870-0E0446A3-F07A-4323-8B17-3F843D9A582FQ38746885-1FBFEBAF-48D7-4BA2-A2B3-C627A59D1A50Q38790829-CA76DD0E-B71B-429B-A1F6-A8AEC945A67EQ38795063-03565FDD-7958-42A6-93B2-3B3985603167Q38804845-EDF0E331-75B4-49F2-A5BC-B2789AD8230BQ38969858-30E33329-EF44-4C27-B20D-FCFA514F6D08Q40066050-6C45F832-A948-46C1-8337-5834D5BC8A21Q40343596-92DFA908-25D7-4416-9D59-3FFFE5D918EDQ40657337-30516B50-0CF0-4324-B92E-D3E831C4F1FBQ40812418-E9C84437-F553-4A6C-B5D8-D199673F4DEEQ41043950-A307991B-C076-4990-A6E0-70AACBB87C9FQ41879630-691CBDEC-9173-4215-A004-F6549DB46F6AQ42079499-8BF61A7F-EC0A-42D8-8969-03AABCBBDD09Q42177793-CFCFA04E-3538-4DD0-84A5-F4ADB5885FB8Q42283077-257978C9-4400-4343-8A13-F68C4C76C7ADQ42670722-684D8CCC-92FA-42BF-94CF-8B1F340D5E22Q44489428-9385407B-2CC8-4A53-A432-A4B38BFA90FE
P2860
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@ast
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@en
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@nl
type
label
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@ast
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@en
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@nl
prefLabel
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@ast
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@en
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@nl
P2860
P3181
P1433
P1476
The BCL2 Family: Key Mediators ...... rgeted Anticancer Therapeutics
@en
P2093
Anthony C Faber
Jeffrey A Engelman
P2860
P304
P3181
P356
10.1158/2159-8290.CD-15-0011
P407
P50
P577
2015-05-01T00:00:00Z